**Items which should not be routinely prescribed in primary care guidance – implementation resources**

NHS England has recently issued guidance “Items which should not routinely be prescribed in primary care: Guidance for CCGs” in relation to 18 drugs which are advised not to be routinely prescribed in primary care <https://www.engage.england.nhs.uk/consultation/items-routinely-prescribed/>. The table below contains links to PAD policy statements, patient information leaflets, letters to patients and other resources which can be used to support implementation of this guidance. **Note: No new patients should be initiated on any of the 18 drugs**.

|  |  |  |
| --- | --- | --- |
| **Medicine** | **NHS England guidance and PCN policy statement** | **Implementation Resources** |
| **Co-proxamol** | Do not initiate  Plan to deprescribe  Recommendation made for inclusion on “Black List” Part XVIIIA of the Drug Tariff.  [PCN policy](http://pad.res360.net/Content/Documents/PCN%20306-2018%20Coproxamol%20Policy%20Statement.pdf) | Letter inviting patient for review    Patient information leaflet |
| **Dosulepin** | Do not initiate  Plan to deprescribe  Exceptional cases with MDT support\*\*  [PCN policy](http://pad.res360.net/Content/Documents/PCN%20314-2018%20Dosulepin%20Policy%20Statement.pdf) | Letter inviting patient for review    Patient information leaflet    Surrey prescribing advice from SABP |
| **Doxazosin MR** | Do not initiate  Plan to review and change medicine  No exception for secondary care  [PCN Policy](http://pad.res360.net/Content/Documents/PCN%20307-2018%20Prolonged%20release%20doxazosin%20Policy%20Statement.pdf) | Letter inviting patient for review    Patient information leaflet    Advice on converting MR to immediate release tablets |
| **Fentanyl Immediate Release** | Do not initiate  Plan to deprescribe  Exceptional cases allowed with MDT support  May be initiated by specialist palliative care teams aligned with NICE guidance [at least 60mg oral morphine and NOT first line breakthrough option]  [PCN policy](http://pad.res360.net/Content/Documents/PCN%20316-2018%20IR%20fentanyl%20Policy%20Statement.pdf) | Letter inviting patient for review    Patient information leaflet |
| **Glucosamine and Chondroitin** | Do not to initiate  GP’s to cease prescribing for current patients  Recommendation made for inclusion on “Black List” Part XVIIIA of the Drug Tariff.  [PCN Policy](http://pad.res360.net/Content/Documents/PCN%20308-2018%20Glucosamine%20and%20Chondroitin%20Policy%20Statement.pdf) | Letter to patient for cessation of prescribing    Patient information leaflet |
| **Herbal Treatments** | Do not prescribe  Recommendation made for inclusion on “Black List” Part XVIIIA of the Drug Tariff.  [PCN Policy](http://pad.res360.net/Content/Documents/PCN%20302-2018%20Herbal%20treatments%20Policy%20Statement.pdf) | Letter to patient for cessation of prescribing    Patient information leaflet |
| **Homeopathy** | Do not prescribe  Recommendation made for inclusion on “Black List” Part XVIIIA of the Drug Tariff.  [PCN Policy](http://pad.res360.net/Content/Documents/PCN%20303-2018%20Homeopathy%20Policy%20Statement.pdf) | Letter to patient for cessation of prescribing    Patient Information leaflet |
| **Lidocaine Plasters** | Do not initiate, except for Post Herpetic Neuralgia if NICE CG173 has been followed  Exceptional cases with MDT support\*\*  [PCN Policy](http://pad.res360.net/Content/Documents/PCN%20317%202018%20Lidocaine%20plasters%20Policy%20Statement.pdf) | Letter inviting patient for review    Patient information leaflet |
| **Liothyronine** | Do not initiate  Referral to and review by an NHS Endocrinologist required for current users  [PCN Policy](http://pad.res360.net/Content/Documents/PCN%20192-2016%20Thyroid%20extracts%20in%20the%20management%20of%20Hypothyroidism.pdf) | Letter inviting patient for review    Consultant letter    Patient information leaflet |
| **Lutein and antioxidants [eg Vits A C E and Zinc for ARMD]** | Do not prescribe  Recommendation made for inclusion on “Black List” Part XVIIIA of the Drug Tariff.  [PCN Policy](http://pad.res360.net/Content/Documents/PCN%20309-2018%20Lutein%20and%20antioxidants%20Policy%20Statement.pdf) | Letter to patient for cessation of prescribing    Patient information leaflet |
| **Omega 3 Fatty Acid Compounds** | Do not prescribe  Recommendation made for inclusion on “Black List” Part XVIIIA of the Drug Tariff.  [PCN Policy](http://pad.res360.net/Content/Documents/PCN%20328-2018%20OMEGA%203%20other%20indications.pdf) | Letter to patient for cessation of prescribing    Patient information leaflet |
| **Oxycodone + Naloxone Combination** | Do not initiate  Plan to deprescribe  Exceptional cases with MDT support\*\*  [PCN Policy](http://pad.res360.net/Content/Documents/PCN%20315-2018%20Oxycodone%20and%20naloxone%20Policy%20Statement.pdf) | Letter inviting patient for review    Patient information leaflet |
| **Paracetamol + Tramadol Combination** | Do not initiate  Plan to deprescribe  [PCN Policy](http://pad.res360.net/Content/Documents/PCN%20311-2018%20Paracetamol%20and%20tramadol%20combination%20product%20Policy%20Statement.pdf) | Letter inviting patient for review    Patient information leaflet |
| **Perindopril Arginine** | GP’s to switch any patient on arginine salt  [PCN Policy](http://pad.res360.net/Content/Documents/PCN%20304-2018%20Perindopril%20arginine%20Policy%20Statement.pdf) | Letter explaining switch to perindopril erbumine    Patient information leaflet |
| **Rubifacients** | Do not initiate  Plan to deprescribe  [PCN Policy](https://surreyccg.res-systems.net/pad/Content/Documents/2/PCN%20312-2018%20Rubefacients%20Policy%20Statement.pdf) | Letter to patient for cessation of prescribing    Patient information leaflet |
| **Tadalafil Once Daily** | GPs are advised not to prescribe once daily Tadalafil and to review and switch patients to alternative  [PCN Policy](http://pad.res360.net/Content/Documents/PCN%20313-2018%20Once%20daily%20tadalafil%20Policy%20Statement.pdf) | Letter inviting patient for review    Patient information letter |
| **Travel Vaccines** | These vaccines should not be prescribed under the NHS for exclusively travel purposes:  Hepatitis B  Japanses Encephalitis  Meningitis ACWY  Yellow Fever  Tickborne encephalitis  Rabies  BCG  [PCN Policy](http://pad.res360.net/Content/Documents/Travel%20Vaccines%20-%20Policy%20statement%20MCG%2003-2017%20-%20Apr%202017.pdf) | [Surrey guidance for practices on payments for vaccines](http://pad.res360.net/Content/Documents/Guidance%20on%20Payments%20for%20Vaccines%20-%20FINAL%20Aug%2017.pdf)  Patient information leaflet |
| **Trimipramine** | Do not initiate  Plan to review and deprescribe or consider alternatives  No exception for MDT prescribing  [PCN Policy](http://pad.res360.net/Content/Documents/PCN%20305-2018%20Trimipramine%20Policy%20Statement.pdf) | Letter inviting patient for review    Patient information leaflet    Surrey prescribing advice from SABP |

Agreed by Surrey Downs Medicines Optimisation Group

Date: April 2018

Review date: April 2021